Věra Adámková
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Věra Adámková has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jolana Mrázková
Experimental Medicine Centre Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic
4 shared publications - Martin Kotrč
Department of Cardiology Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic
4 shared publications - Peter Wohlfahrt
Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
4 shared publications - Vojtech Melenovsky
Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
4 shared publications - Dominik Jenča
Department of Cardiology Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic
3 shared publications - Jan Pitha
Department of Cardiology, Laboratory for Atherosclerosis Research, Institute of Clinical and Experimental Medicine, Prague, Czech Republic -
3 shared publications
Latest Publications
- Open Access
- 21 May 2024
- Published by Taylor & Francis in Annals of Human Biology
- Vol. 51 (1) , 2341727
Increased prevalence of the COVID-19 associated Neanderthal mutations in the Central European Roma population
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent COVID-19 has spread world-wide and become pandemic with about 7 million deaths reported so far. Interethnic variability of the disease has been described, but a significant part of the differences remain unexplained and may be attributable to genetic factors. To analyse genetic factors potentially influencing COVID-19 susceptibility and severity in European Roma minority. Two genetic determinants, within OAS-1 (2-prime,5-prime-oligoadenylate synthetase 1, a key protein in the defence against viral infection; it activates RNases that degrade viral RNAs; rs4767027 has been analysed) and LZTFL1 (leucine zipper transcription factor-like 1, expressed in the lung respiratory epithelium; rs35044562 has been analysed) genes were screened in a population-sample of Czech Roma (N = 302) and majority population (N = 2,559). For both polymorphisms, Roma subjects were more likely carriers of at least one risky allele for both rs4767027-C (p < 0.001) and rs35044562-G (p < 0.00001) polymorphism. There were only 5.3% Roma subjects without at least one risky allele in comparison with 10.1% in the majority population (p < 0.01). It is possible that different genetic background plays an important role in increased prevalence of COVID-19 in the Roma minority.
- 21 May 2024
- Published by Taylor & Francis in Annals of Human Biology
- Vol. 51 (1) , 2341727
Open AccessIncreased prevalence of the COVID-19 associated Neanderthal mutations in the Central European Roma population
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent COVID-19 has spread world-wide and become pandemic with about 7 million deaths reported so far. Interethnic variability of the disease has been described, but a significant part of the differences remain unexplained and may be attributable to genetic factors. To analyse genetic factors potentially influencing COVID-19 susceptibility and severity in European Roma minority. Two genetic determinants, within OAS-1 (2-prime,5-prime-oligoadenylate synthetase 1, a key protein in the defence against viral infection; it activates RNases that degrade viral RNAs; rs4767027 has been analysed) and LZTFL1 (leucine zipper transcription factor-like 1, expressed in the lung respiratory epithelium; rs35044562 has been analysed) genes were screened in a population-sample of Czech Roma (N = 302) and majority population (N = 2,559). For both polymorphisms, Roma subjects were more likely carriers of at least one risky allele for both rs4767027-C (p < 0.001) and rs35044562-G (p < 0.00001) polymorphism. There were only 5.3% Roma subjects without at least one risky allele in comparison with 10.1% in the majority population (p < 0.01). It is possible that different genetic background plays an important role in increased prevalence of COVID-19 in the Roma minority.
- Open Access
- 16 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (2) , e032505
Remote Heart Failure Symptoms Assessment After Myocardial Infarction Identifies Patients at Risk for Death
Background: Heart failure is a common complication after myocardial infarction (MI) and is associated with increased mortality. Whether remote heart failure symptoms assessment after MI can improve risk stratification is unknown. The authors evaluated the association of the 23‐item Kansas City Cardiomyopathy Questionnaire (KCCQ) with all‐cause mortality after MI. Methods and Results: Prospectively collected data from consecutive patients hospitalized for MI at a large tertiary heart center between June 2017 and September 2022 were used. Patients remotely completed the KCCQ 1 month after discharge. A total of 1135 (aged 64±12 years, 26.7% women) of 1721 eligible patients completed the KCCQ. Ranges of KCCQ scores revealed that 30 (2.6%), 114 (10.0%), 274 (24.1%), and 717 (63.2%) had scores P <0.001). Adding the 30‐day KCCQ to clinical risk factors improved risk stratification: change in area under the curve of 2.6 (95% CI, 0.3–5.0), Brier score of −0.6 (95% CI, −1.0 to −0.2), and net reclassification improvement of 0.71 (95% CI, 0.45–1.04). KCCQ items most strongly associated with mortality were walking impairment, leg swelling, and change in symptoms. Conclusions: Remote evaluation of heart failure symptoms using the KCCQ among patients recently discharged for MI identifies patients at risk for mortality. Whether closer follow‐up and targeted therapy can reduce mortality in high‐risk patients warrants further study.
- 16 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (2) , e032505
Open AccessRemote Heart Failure Symptoms Assessment After Myocardial Infarction Identifies Patients at Risk for Death
Background: Heart failure is a common complication after myocardial infarction (MI) and is associated with increased mortality. Whether remote heart failure symptoms assessment after MI can improve risk stratification is unknown. The authors evaluated the association of the 23‐item Kansas City Cardiomyopathy Questionnaire (KCCQ) with all‐cause mortality after MI. Methods and Results: Prospectively collected data from consecutive patients hospitalized for MI at a large tertiary heart center between June 2017 and September 2022 were used. Patients remotely completed the KCCQ 1 month after discharge. A total of 1135 (aged 64±12 years, 26.7% women) of 1721 eligible patients completed the KCCQ. Ranges of KCCQ scores revealed that 30 (2.6%), 114 (10.0%), 274 (24.1%), and 717 (63.2%) had scores P <0.001). Adding the 30‐day KCCQ to clinical risk factors improved risk stratification: change in area under the curve of 2.6 (95% CI, 0.3–5.0), Brier score of −0.6 (95% CI, −1.0 to −0.2), and net reclassification improvement of 0.71 (95% CI, 0.45–1.04). KCCQ items most strongly associated with mortality were walking impairment, leg swelling, and change in symptoms. Conclusions: Remote evaluation of heart failure symptoms using the KCCQ among patients recently discharged for MI identifies patients at risk for mortality. Whether closer follow‐up and targeted therapy can reduce mortality in high‐risk patients warrants further study.
- Open Access
- 21 March 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (6) , e028987
Attenuation of Hypocretin/Orexin Signaling Is Associated With Increased Mortality After Myocardial Infarction
Background: The hypocretin/orexin system has been shown to play a role in heart failure. Whether it also influences myocardial infarction (MI) outcomes is unknown. We evaluated the effect of the rs7767652 minor allele T associated with decreased transcription of the hypocretin/orexin receptor‐2 and circulating orexin A concentrations on mortality risk after MI. Methods and Results: Data from a single‐center, prospectively designed registry of consecutive patients hospitalized for MI at a large tertiary cardiology center were analyzed. Patients without previous history of MI or heart failure were included. A random population sample was used to compare allele frequencies in the general population. Out of 1009 patients (aged 64±12 years, 74.6% men) after MI, 6.1% were homozygotes (TT) and 39.4% heterozygotes (CT) for minor allele. Allele frequencies in the MI group did not differ from 1953 subjects from general population (χ 2 P =0.62). At index hospitalization, MI size was the same, but ventricular fibrillation and the need for cardiopulmonary resuscitation were more prevalent in the TT allele variant. Among patients with ejection fraction ≤40% at discharge, the TT variant was associated with a lower increase in left ventricular ejection fraction during follow‐up ( P =0.03). During the 27‐month follow‐up, there was a statistically significant association of the TT variant with increased mortality risk (hazard ratio [HR], 2.83; P =0.001). Higher circulating orexin A was associated with a lower mortality risk (HR, 0.41; P <0.05). Conclusions: Attenuation of hypocretin/orexin signaling is associated with increased mortality risk after MI. This effect may be partially explained by the increased arrhythmic risk and the effect on the left ventricular systolic function recovery.
- 21 March 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (6) , e028987
Open AccessAttenuation of Hypocretin/Orexin Signaling Is Associated With Increased Mortality After Myocardial Infarction
Background: The hypocretin/orexin system has been shown to play a role in heart failure. Whether it also influences myocardial infarction (MI) outcomes is unknown. We evaluated the effect of the rs7767652 minor allele T associated with decreased transcription of the hypocretin/orexin receptor‐2 and circulating orexin A concentrations on mortality risk after MI. Methods and Results: Data from a single‐center, prospectively designed registry of consecutive patients hospitalized for MI at a large tertiary cardiology center were analyzed. Patients without previous history of MI or heart failure were included. A random population sample was used to compare allele frequencies in the general population. Out of 1009 patients (aged 64±12 years, 74.6% men) after MI, 6.1% were homozygotes (TT) and 39.4% heterozygotes (CT) for minor allele. Allele frequencies in the MI group did not differ from 1953 subjects from general population (χ 2 P =0.62). At index hospitalization, MI size was the same, but ventricular fibrillation and the need for cardiopulmonary resuscitation were more prevalent in the TT allele variant. Among patients with ejection fraction ≤40% at discharge, the TT variant was associated with a lower increase in left ventricular ejection fraction during follow‐up ( P =0.03). During the 27‐month follow‐up, there was a statistically significant association of the TT variant with increased mortality risk (hazard ratio [HR], 2.83; P =0.001). Higher circulating orexin A was associated with a lower mortality risk (HR, 0.41; P <0.05). Conclusions: Attenuation of hypocretin/orexin signaling is associated with increased mortality risk after MI. This effect may be partially explained by the increased arrhythmic risk and the effect on the left ventricular systolic function recovery.
- Open Access
- 14 November 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 1051995
Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions
Background: Left ventricular ejection fraction (EF) is an independent predictor of adverse outcomes after myocardial infarction (MI). However, current data on trajectories and determinants of EF are scarce. The present study aimed to describe the epidemiology of EF after MI.Methods: Data from a single-center prospectively-designed registry of consecutive patients hospitalized at a large tertiary cardiology center were utilized.Results: Out of 1,593 patients in the registry, 1,065 were hospitalized for MI type I (65.4% STEMI) and had no previous history of heart failure or MI. At discharge, EF < 40% was present in 238 (22.3%), EF 40–50% in 326 (30.6%) and EF > 50% in 501 (47.0%). Patients with EF < 40% were often those who suffered subacute and anterior STEMI, had higher heart rate at admission and higher maximal troponin level, and had more often HF signs requiring intravenous diuretics. Among subjects with EF < 40%, the follow-up EF was available in 166 (80% of eligible). Systolic function recovered to EF > 50% in 39 (23.1%), slightly improved to EF 40–50% in 44 (26.0%) and remained below 40% in 86 (50.9%). Systolic function improvement to EF > 40% was predicted by lower severity of coronary atherosclerosis, lower leukocyte count, and the absence of atrial fibrillation.Conclusions: Despite recent improvements in in-hospital MI care, one in five patients has systolic dysfunction at hospital discharge. Out of these, EF improves in 51%, and full recovery is observed in 23%. The severity of coronary atherosclerosis, inflammatory response to MI, and atrial fibrillation may affect EF recovery.
- 14 November 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 1051995
Open AccessTrajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions
Background: Left ventricular ejection fraction (EF) is an independent predictor of adverse outcomes after myocardial infarction (MI). However, current data on trajectories and determinants of EF are scarce. The present study aimed to describe the epidemiology of EF after MI.Methods: Data from a single-center prospectively-designed registry of consecutive patients hospitalized at a large tertiary cardiology center were utilized.Results: Out of 1,593 patients in the registry, 1,065 were hospitalized for MI type I (65.4% STEMI) and had no previous history of heart failure or MI. At discharge, EF < 40% was present in 238 (22.3%), EF 40–50% in 326 (30.6%) and EF > 50% in 501 (47.0%). Patients with EF < 40% were often those who suffered subacute and anterior STEMI, had higher heart rate at admission and higher maximal troponin level, and had more often HF signs requiring intravenous diuretics. Among subjects with EF < 40%, the follow-up EF was available in 166 (80% of eligible). Systolic function recovered to EF > 50% in 39 (23.1%), slightly improved to EF 40–50% in 44 (26.0%) and remained below 40% in 86 (50.9%). Systolic function improvement to EF > 40% was predicted by lower severity of coronary atherosclerosis, lower leukocyte count, and the absence of atrial fibrillation.Conclusions: Despite recent improvements in in-hospital MI care, one in five patients has systolic dysfunction at hospital discharge. Out of these, EF improves in 51%, and full recovery is observed in 23%. The severity of coronary atherosclerosis, inflammatory response to MI, and atrial fibrillation may affect EF recovery.
- Open Access
- 1 May 2022
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (Supplement)
Interleukin-6 predicts recovery of systolic function after myocardial infarction
Funding Acknowledgements: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Ministry of Health of the Czech Republic Background: Interleukin (IL)-6 is an important mediator of the inflammatory response to acute myocardial infarction (MI). Increased IL-6 levels are associated with adverse outcomes after MI. However, there are only limited data on the association of IL-6 levels with recovery of systolic function after MI. Purpose: The aim of the present study was to evaluate the independent predictive value of IL-6 level for recovery of systolic function among patients hospitalized for their first MI. Methods: Consecutive patients without previous history of MI or cardiomyopathy with left ventricular ejection fraction (LVEF) ≤40% measured by transthoracic echocardiography upon hospital discharge and available follow-up LVEF evaluated between 3 months and one year since hospital discharge were selected from a prospective registry of MI patients (n=1323). Results: In total, data from 183 patients (mean age 64.2±11.2, 29% female, mean EF upon discharge 32.6±5.8) were analyzed. In the multivariate linear regression, IL-6 level measured within 24 hours from the hospital admission was positively associated with NT-proBNP, maximal hs-Troponin T a glycemia level and negatively with female gender, total cholesterol and admission systolic blood pressure. During follow-up, LVEF increased by 6.1±9.0% and LVEF recovered to value >50% in 43 (23.5%) patients. In the multivariate analysis, LVEF improvement was predicted by lower IL-6, lower maximal troponin level, female gender, lower heart rate at the time of hospital admission and Killip class I. In the ROC analysis (AUC 0.72, p<0.001), IL-6 ≤ 15.7ng/L had 51% sensitivity and 87% specificity to predict LVEF recovery. Conclusion: The inflammatory response to MI, as assessed by IL-6, is associated with MI size, glucose and lipid metabolism and is lower in women. IL-6 independently predicts change in LVEF among patients with moderate to severe LV dysfunction. This supports previous findings that IL-6 inhibition can increase myocardial salvage after MI and identifies possible patients that may benefit from targeted therapy.
- 1 May 2022
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (Supplement)
Open AccessInterleukin-6 predicts recovery of systolic function after myocardial infarction
Funding Acknowledgements: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Ministry of Health of the Czech Republic Background: Interleukin (IL)-6 is an important mediator of the inflammatory response to acute myocardial infarction (MI). Increased IL-6 levels are associated with adverse outcomes after MI. However, there are only limited data on the association of IL-6 levels with recovery of systolic function after MI. Purpose: The aim of the present study was to evaluate the independent predictive value of IL-6 level for recovery of systolic function among patients hospitalized for their first MI. Methods: Consecutive patients without previous history of MI or cardiomyopathy with left ventricular ejection fraction (LVEF) ≤40% measured by transthoracic echocardiography upon hospital discharge and available follow-up LVEF evaluated between 3 months and one year since hospital discharge were selected from a prospective registry of MI patients (n=1323). Results: In total, data from 183 patients (mean age 64.2±11.2, 29% female, mean EF upon discharge 32.6±5.8) were analyzed. In the multivariate linear regression, IL-6 level measured within 24 hours from the hospital admission was positively associated with NT-proBNP, maximal hs-Troponin T a glycemia level and negatively with female gender, total cholesterol and admission systolic blood pressure. During follow-up, LVEF increased by 6.1±9.0% and LVEF recovered to value >50% in 43 (23.5%) patients. In the multivariate analysis, LVEF improvement was predicted by lower IL-6, lower maximal troponin level, female gender, lower heart rate at the time of hospital admission and Killip class I. In the ROC analysis (AUC 0.72, p<0.001), IL-6 ≤ 15.7ng/L had 51% sensitivity and 87% specificity to predict LVEF recovery. Conclusion: The inflammatory response to MI, as assessed by IL-6, is associated with MI size, glucose and lipid metabolism and is lower in women. IL-6 independently predicts change in LVEF among patients with moderate to severe LV dysfunction. This supports previous findings that IL-6 inhibition can increase myocardial salvage after MI and identifies possible patients that may benefit from targeted therapy.
- Open Access
- 24 June 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (9) , e1361
Different prevalence of T2DM risk alleles in Roma population in comparison with the majority Czech population
Background: The Czech governmental study suggests up to a 25% higher prevalence of type 2 diabetes mellitus (T2DM) in the Roma population than within the majority population. It is not known whether and to what extent these differences have a genetic background.Methods: To analyze whether the frequencies of the alleles/genotypes of theFTO,TCF7L2,CDKN2A/2B,MAEA,TLE4,IGF2BP2,ARAP1,andKCNJ11genes differ between the two major ethnic groups in the Czech Republic, we examined them in DNA samples from 302 Roma individuals and 298 Czech individuals.Results: Compared to the majority population, Roma are more likely to carry risk alleles in theFTO(26% vs. 16% GG homozygotes,p < .01),IGF2BP2(22% vs. 10% TT homozygotes,p < .0001),ARAP1(98% vs. 95% of A allele carriers,p < .005), andCDKN2A/2B(81% vs. 66% of TT homozygotes,p < .001) genes; however, less frequently they are carriers of theTCF7L2risk allele (34% vs. 48% of the T allelep < .0005). Finally, we found significant accumulation of T2DM‐associated alleles between the Roma population in comparison with the majority population (25.4% vs. 15.2% of the carriers of at least 12 risk alleles;p < .0001).Conclusion: The increased prevalence of T2DM in the Roma population may have a background in different frequencies of the risk alleles of genes associated with T2DM development.
- 24 June 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (9) , e1361
Open AccessDifferent prevalence of T2DM risk alleles in Roma population in comparison with the majority Czech population
Background: The Czech governmental study suggests up to a 25% higher prevalence of type 2 diabetes mellitus (T2DM) in the Roma population than within the majority population. It is not known whether and to what extent these differences have a genetic background.Methods: To analyze whether the frequencies of the alleles/genotypes of theFTO,TCF7L2,CDKN2A/2B,MAEA,TLE4,IGF2BP2,ARAP1,andKCNJ11genes differ between the two major ethnic groups in the Czech Republic, we examined them in DNA samples from 302 Roma individuals and 298 Czech individuals.Results: Compared to the majority population, Roma are more likely to carry risk alleles in theFTO(26% vs. 16% GG homozygotes,p < .01),IGF2BP2(22% vs. 10% TT homozygotes,p < .0001),ARAP1(98% vs. 95% of A allele carriers,p < .005), andCDKN2A/2B(81% vs. 66% of TT homozygotes,p < .001) genes; however, less frequently they are carriers of theTCF7L2risk allele (34% vs. 48% of the T allelep < .0005). Finally, we found significant accumulation of T2DM‐associated alleles between the Roma population in comparison with the majority population (25.4% vs. 15.2% of the carriers of at least 12 risk alleles;p < .0001).Conclusion: The increased prevalence of T2DM in the Roma population may have a background in different frequencies of the risk alleles of genes associated with T2DM development.
- Open Access
- 1 June 2015
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 35, 29-33
Rates and predictors of genital warts burden in the Czech population
- 1 June 2015
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 35, 29-33
Open AccessRates and predictors of genital warts burden in the Czech population
- 1 June 2011
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29, e111-e112
CARDIOVASCULAR RISK FACTORS BY BLOOD PRESSURE CATEGORIES IN A CZECH POPULATION RANDOM SAMPLE. CROSS-SECTIONAL DATA AND LONGITUDINAL TRENDS
- 1 June 2011
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29, e111-e112
CARDIOVASCULAR RISK FACTORS BY BLOOD PRESSURE CATEGORIES IN A CZECH POPULATION RANDOM SAMPLE. CROSS-SECTIONAL DATA AND LONGITUDINAL TRENDS
- Open Access
- 5 April 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 51
Higher prevalence of smoking and lower BMI, waist circumference, cholesterol and triacylglyceride levels in Prague's homeless compared to a majority of the Czech population
Homeless people have higher morbidity and mortality rates than the general population. Research has shown that cardiovascular disease is the leading cause of death in older homeless adults. This study was undertaken to describe the prevalence of cardiovascular risk factors in the homeless population in Prague.
- 5 April 2007
- Published by Springer Nature in BMC Public Health
- Vol. 7 (1) , 51
Open AccessHigher prevalence of smoking and lower BMI, waist circumference, cholesterol and triacylglyceride levels in Prague's homeless compared to a majority of the Czech population
Homeless people have higher morbidity and mortality rates than the general population. Research has shown that cardiovascular disease is the leading cause of death in older homeless adults. This study was undertaken to describe the prevalence of cardiovascular risk factors in the homeless population in Prague.